Lawmakers Press FDA about IV Drug Shortages

Feb 05, 2018 - 02:24 PM

A bipartisan group of 30 senators and 64 representatives Friday asked Food and Drug Administration Commissioner Scott Gottlieb, M.D., to take all available action to address current intravenous saline shortages affecting hospitals across the country. “To avoid any further harm to consumers, we request that the FDA use every authority at its disposal to address this crisis and present a plan to ensure immediate and sustained production of IV bags that also provides sufficient guidance to mitigate cost increases,” the letter states. “We understand the FDA has taken steps to attempt to remedy this crisis by allowing the importation of saline products from other countries and by also approving new saline products. However, providers in our states have voiced concerns over the uncertainty of when these products will become available and when a long-term solution to this shortage will be implemented.” The letter was spearheaded by Rep. Marcy Kaptur (D-OH), Del. Jenniffer Gonzalez-Colon (R-PR), and Sens. Marco Rubio (R-FL) and Richard Blumenthal (D-CT).

Related News Articles

Headline
Research finds drug prices increased without adding new clinical benefits
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…
Headline
AHA responds to Medicare $2 Drug List Model request for information
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
CMS releases RFI, sample list of prescription drugs that may be included under proposed Medicare $2 Drug List Model 
The Centers for Medicare & Medicaid Services Oct. 9 released a request for information and a sample list of prescription drugs it intends to include under…
Headline
Reminder: CMS hosting webinar Oct. 21 on price transparency machine-readable file 2025 requirements 
The Centers for Medicare & Medicaid Services Oct. 21 will host a webinar on meeting its new hospital price transparency requirements becoming effective Jan…
Headline
HHS issues final guidance for second cycle of drug price negotiations 
The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug…
Headline
Medicare Advantage, prescription drug programs to remain stable for 2025 
The Centers for Medicare & Medicaid Services Sept. 27 announced that average premiums, benefits and plan choices for Medicare Advantage and Part D will…